$7.05
0.253.6%
最終更新: Oct 9, 7:15 PM
$7.01
0.202.94%
Benzinga
Benzinga
Benzinga
土曜日, 10 10
Benzinga
© 2026 Benzinga | All Rights Reserved
Emergent BioSolutions (EBS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Emergent BioSolutions (EBS) は、8 5, 2026日にQ3の2026に関するガイダンスを直近で発表しました。同社は当期の売上高を$110M - $130Mの範囲と予想しています。
以前のガイダンスと比較して、Emergent BioSolutionsは売上高予測を以前の範囲である引き下げから$645M - $675Mに引き上げました。
Emergent BioSolutionsは、24から11 8, 2022の間に8 5, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 5 times and lowered it 9 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.11 | $-0.25 | $0.32 | $-0.03 |
| Actual | $0.60 | $0.21 | $-0.43 | $1.06 |
| Surprise | +445.5% | +184.0% | -234.4% | +3633.3% |
| Revenue | ||||
| Estimate | $179.4M | $157.4M | $216.5M | $198.6M |
| Actual | $234.3M | $156.1M | $148.7M | $231.1M |
| Surprise | +30.6% | -0.83% | -31.3% | +16.4% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.40 | $-0.10 | $-0.53 | $0.23 |
| Revenue | ||||
| Consensus | $123.2M | $142.7M | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $0.60 | $0.11 | 445.5 % |
| Q1 | Apr 30, 2026 | $0.21 | $-0.25 | 184.0 % |
| Q4 | Feb 26, 2026 | $-0.43 | $0.32 | -234.4 % |
| Q3 | Oct 29, 2025 | $1.06 | $-0.03 | 3633.3 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $234.30M | $179.40M | 30.6 % |
| Q1 | Apr 30, 2026 | $156.10M | $157.40M | -0.83 % |
| Q4 | Feb 26, 2026 | $148.70M | $216.50M | -31.3 % |
| Q3 | Oct 29, 2025 | $231.10M | $198.60M | 16.4 % |